ArticleBritish journal of cancer2023

Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).

Giulia Orsi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.